RxDoctor Payments Data

Brenda Shanley

Psychiatric/Mental Health · Spokane, WANPI 1083639207

Payments from drug & device makers

$554in general payments, 2019–2025

Across 21 payments — averaging $26.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$158
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$92
  • Johnson & Johnson$79
  • Neurocrine Biosciences, Inc.$70
  • Otsuka America Pharmaceutical, Inc.$69
  • Lundbeck LLC$40
  • plus $46 from 2 others

What the payments were for

  • Food & beverage$554100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$554 in reported general payments places this provider in the 65th percentile of 931 psychiatric/mental health providers in Washington.

See all psychiatric/mental health providers in Washington

Medicare billing

Part B allowed, 2024
$5,220
Medicare patients
35
Services billed
125

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate283$1,008,223
AustedoDeutetrabenazine21$183,230
Abilify MaintenaAripiprazole40$117,669
Olanzapine OdtOlanzapine392$32,278
Paliperidone ErPaliperidone68$31,893
Clozapine304$26,485
Risperdal ConstaRisperidone Microspheres20$23,597
Divalproex Sodium ErDivalproex Sodium353$23,328
Olanzapine930$22,679
Tetrabenazine20$20,920
Quetiapine Fumarate768$17,444
Chlorpromazine Hcl44$16,315
Divalproex Sodium301$14,839
Clomipramine Hcl28$10,755
Trazodone Hcl781$10,746

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Risperdal Consta$79$1,031,820303 claims
Teva Pharmaceuticals USA, Inc.Austedo$158$183,23021 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$69$117,66940 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 931 psychiatric/mental health providers in Washington.

Other psychiatric/mental health in Spokane

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →